{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-002306","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.482515+00:00","generated_at":"2026-06-19T03:48:53.866409+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MannKind reports 2022 total revenues of $100M, up 32% YoY; Tyvaso DPI royalties $16M","bullets":["Q4 2022 total revenues $36.1M (+188% YoY); full-year $99.8M (+32% vs 2021).","Afrezza net revenue $43.3M in 2022 (+11%); V-Go contributed $12.9M after Q2 acquisition.","Tyvaso DPI royalties $15.6M in 2022 ($9.1M in Q4); $37.9M manufacturing revenue deferred.","Cash and investments $172.8M at Dec 31, 2022; INHALE-1 pediatric trial 50% enrolled.","Inhaled clofazimine (MNKD-101) to enter adaptive Phase 2/3 study in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-002306","json":"https://secwatch.observer/filing/0001564590-23-002306.json","markdown":"https://secwatch.observer/filing/0001564590-23-002306.md","text":"https://secwatch.observer/filing/0001564590-23-002306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000156459023002306/0001564590-23-002306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000156459023002306/mnkd-8k_20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:48:53.866409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}